ScholarLens Back to search
2017•NeurologyRequires access

Comparison of treatment retention and efficacy outcomes with fingolimod, interferons and glatiramer acetate in PREFERMS (P6.369)

Florian P. Thomas, Douglas L. Arnold, Mark Cascione, Edward Fox, Maria Cecilia Vieira, Jennifer S. Ko, Xiangyi Meng, Lesley Schofield, Fernanda Boulos, Nadia Tenenbaum, Bruce Cree

Open publisher page 0 citations

Abstract

To compare therapy retention with fingolimod versus specific injectable disease-modifying therapies (iDMTs) in patients with relapsing–remitting multiple sclerosis (RRMS).

About this research paper

What this paper is about

To compare therapy retention with fingolimod versus specific injectable disease-modifying therapies (iDMTs) in patients with relapsing–remitting multiple sclerosis (RRMS).

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To compare therapy retention with fingolimod versus specific injectable disease-modifying therapies (iDMTs) in patients with relapsing–remitting multiple sclerosis (RRMS).

Key concepts: Fingolimod, Glatiramer acetate, Multiple sclerosis, Medicine, Pharmacology, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Comparison of treatment retention and efficacy outcomes with fingolimod, interferons and glatiramer acetate in PREFERMS (P6.369) — Research Paper | ScholarLens